Serial Number: 10/613,914 Filing Date: July 3, 2003 Title: THERAPEUTIC AMIDES

## IN THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) A compound of formula (I):

$$X \longrightarrow A$$
 $O \longrightarrow C$ 
 $CH_3$ 
(I)

wherein

A is CH or N;

X is F, Cl, or Br;

Y is hydrogen, hydroxy, or (C<sub>1</sub>-C<sub>7</sub>)alkoxy; and

Z is an amino acid, or heterocycle;

or a pharmaceutically acceptable salt thereof.

- 2. (Original) The compound of claim 1, wherein Y is H.
- 3. (Original) The compound of claim 1, wherein Y is -OH.
- 4. (Original) The compound of claim 1, wherein Y is -OMe.
- 5. (Original) The compound of any of claims 1 to 4 wherein X is -Cl.
- 6. (Original) The compound of any of claims 1 to 4 wherein X is -Br.
- 7. (Original) The compound of any of claims 1 to 6 wherein Z is an amino acid.
- 8. (Original) The compound of any of claims 1 to 6 wherein Z is -NH-(CH<sub>2</sub>)<sub>2</sub>-SO<sub>3</sub>H.

Serial Number: 10/613,914 Filing Date: July 3, 2003 Title: THERAPEUTIC AMIDES

- 9. (Original) The compound of any of claims 1 to 6 wherein Z is -NH-CH<sub>2</sub>-CO<sub>2</sub>H.
- 10. (Original) The compound of any of claims 1 to 6 wherein Z is -NH-CH(CH<sub>3</sub>)-CO<sub>2</sub>H.
- 11. (Original) The compound of any of claims 1 to 6 wherein Z is a nitrogen linked pyrrolidino, piperidino, morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino.
- 12. (Original) A compound of formula (I):

$$X \longrightarrow A$$
 $O \longrightarrow C$ 
 $CH_3$ 
 $(I)$ 

wherein

A is CH;

X is F, Cl, or Br;

Y is hydroxy, or  $(C_1-C_7)$ alkoxy; and

Z is an -NR<sub>a</sub>R<sub>b</sub>;

where  $R_a$  and  $R_b$  is independently hydrogen,  $(C_1-C_7)$ alkyl,  $(C_1-C_7)$ alkanoyl, aryl, aryl $(C_1-\acute{C}_7)$ alkyl, or where  $R_a$  and  $R_b$  together with the nitrogen to which they are attached are a pyrrolidino, piperidino, morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino;

or a pharmaceutically acceptable salt thereof.

- 13. (Original) The compound of claim 12, wherein Y is -OH.
- 14. (Original) The compound of claim 12, wherein Y is -OMe.
- 15. (Original) The compound of any of claims 12 to 14 wherein X is -Cl.

## AMENDMENT AND RESPONSE UNDER 37 CFR § 1.111

Serial Number: 10/613,914 Filing Date: July 3, 2003 Title: THERAPEUTIC AMIDES

- 16. (Original) The compound of any of claims 12 to 14 wherein X is -Br.
- 17. (Original) The compound of any of claims 12 to 16 wherein Z is -NR<sub>a</sub>R<sub>b</sub>.
- 18. (Original) The compound of any of claims 12 to 16 wherein Z is –NH<sub>2</sub>.
- 19. (Original) The compound of any of claims 12 to 16 wherein Z is –NHCH<sub>3</sub>.
- 20. (Original) The compound of any of claims 12 to 16 wherein Z is a nitrogen linked 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino.
- 21. (Original) A compound of formula (I):

$$X \longrightarrow A$$
 $O \longrightarrow C \longrightarrow C = O$ - $Z$ 
(I)

wherein

A is CH;

X is F, Cl, or Br;

Y is hydrogen, hydroxy, or  $(C_1-C_7)$ alkoxy; and

Z is -NR<sub>a</sub>R<sub>b</sub>; and 0

 $R_a$  and  $R_b$  are each independently hydrogen,  $(C_1-C_7)$ alkyl,  $(C_1-C_7)$ alkanoyl, aryl, aryl $(C_1-C_7)$ alkyl, or where  $R_a$  and  $R_b$  together with the nitrogen to which they are attached are a pyrrolidino, piperidino, morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino;

or a pharmaceutically acceptable salt thereof.

- 22. (Original) The compound of claim 21 wherein R<sub>a</sub> and R<sub>b</sub> are each independently (C<sub>1</sub>-C<sub>7</sub>)alkanoyl, aryl, aryl(C<sub>1</sub>-C<sub>7</sub>)alkyl, or where R<sub>a</sub> and R<sub>b</sub> together with the nitrogen to which they are attached are a pyrrolidino, piperidino, morpholino, 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino.
- 23. (Original) The compound of claim 21 or 22 wherein Y is H.
- 24. (Original) The compound of claim 21 or 22 wherein Y is -OH.
- 25. (Original) The compound of claim 21 or 22 wherein Y is -OMe.
- 26. (Original) The compound of any of claims 21 to 25 wherein X is -Cl.
- 27. (Original) The compound of any of claims 21 to 25 wherein X is -Br.
- 28. (Original) The compound of any of claims 21 to 27 wherein Z is -NR<sub>a</sub>R<sub>b</sub>.
- 29. (Original) The compound of any of claims 21 to 27 wherein Z is a nitrogen linked pyrrolidino, piperidino, or morpholino.
- 30. (Original) The compound of any of claims 21 to 27 wherein Z is a nitrogen linked 1,3-benzodiazepino, 1,4-benzodiazepino, or 1,5-benzodiazepino.
- 31-48. (Cancelled)
- 49. (Currently Amended) The compound
  - 2-{4-((7-Bromo-2-quinolinyl)oxy)phenoxy} propionmethylamide;
  - 2-{4-((7-Chloro-2-quinolinyl)oxy)phenoxy} propiondimethylamide;
  - (2-(4-(7-Chloro-2-quinoxalinyl)oxy)phenoxy) propionylamino ethanesulfonic acid;
  - (2-(4-(7-Bromo-2-quinolinyl)oxy)phenoxy) propionylamino ethanesulfonic acid;

- {2-{4-(7-Bromo-quinolin-2-yloxy)phenoxy} propionylamino} acetic acid;
- {2-{4-(7-Chloro-quinoxalin-2-yloxy)-phenoxy} propionyl amino} acetic acid;
- (R) (2-(4-(7-Bromo-2-quinolinyl)oxy)phenoxy) propionylamino ethanesulfonic acid;
- (R) {2-[4-(7-Bromo-quinolin-2-yloxy)-phenoxy]-propionylamino} acetic acid; and
- (R) {2-{4-(7-Chloro quinoxalin-2-yloxy) phenoxy} propionyl amino} acetic acid; or pharmaceutically acceptable salts thereof.
- 50. (Currently Amended) The compound of any of claims 1 to 30 or 49 which is the (R) enantiomer.
- 51. (Currently Amended) The compound of any of claims 1 to 30 or 49 which is the (S) enantiomer.
- 52. (Currently Amended) The compound of any of claims 1 to 30 or 49 to 51 which the compound is isolated and purified.
- 53. (Withdrawn) The compound of claim 52, wherein the compound is a solid.
- 54. (Withdrawn) The compound of claim 52, wherein the compound is a crystalline solid.
- 55. (Withdrawn) A pharmaceutical composition comprising a compound any one of claims 1 to 54 and a pharmaceutically acceptable diluent or carrier.
- 56. (Withdrawn) The pharmaceutical composition of claim 55, wherein the pharmaceutical composition is formulated as a unit dosage form.
- 57. (Withdrawn) The pharmaceutical composition of claim 56, wherein the unit dosage form is formulated for oral administration.

58. (Withdrawn) The pharmaceutical composition of claim 56, wherein the unit dosage form is formulated for administration by injection.

## 59-60. (Cancelled)

- 61. (Currently Amended) A therapeutic method to treat cancer in a mammal, comprising administering to a mammal in need of such therapy an effective amount of a compound of any one of claims 1 to 30 or 49 to 54.
- 62. (Withdrawn) A therapeutic method to treat cancer in a mammal, comprising administering to a mammal in need of such therapy an effective amount of a pharmaceutical composition of of any one of claims 55 to 58.
- 63. (Amended) A therapeutic method to treat cancer in a mammal, comprising coadministering to a mammal in need of such therapy, an effective amount of a mixture of two or more compounds of any one of claims 1 to 30 or 49 to 54.
- 64. (Withdrawn) A therapeutic method to treat cancer in a mammal, comprising coadministering to a mammal in need of such therapy, an effective amount of a mixture of two or more pharmaceutical compositions of any one of claims 55 to 58.